323 related articles for article (PubMed ID: 32978808)
1. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
[TBL] [Abstract][Full Text] [Related]
2. Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.
Mirzaei A; Tavoosidana G; Modarressi MH; Rad AA; Fazeli MS; Shirkoohi R; Tavakoli-Yaraki M; Madjd Z
Tumour Biol; 2015 Jun; 36(6):4801-10. PubMed ID: 25631749
[TBL] [Abstract][Full Text] [Related]
3. The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma.
Di Matteo S; Nevi L; Costantini D; Overi D; Carpino G; Safarikia S; Giulitti F; Napoletano C; Manzi E; De Rose AM; Melandro F; Bragazzi M; Berloco PB; Giuliante F; Grazi G; Giorgi A; Cardinale V; Adorini L; Gaudio E; Alvaro D
PLoS One; 2019; 14(1):e0210077. PubMed ID: 30677052
[TBL] [Abstract][Full Text] [Related]
4. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
5. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
6. lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.
Qiu G; Ma D; Li F; Sun D; Zeng Z
Int J Oncol; 2019 Jul; 55(1):45-58. PubMed ID: 31059014
[TBL] [Abstract][Full Text] [Related]
7. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.
Shafiei S; Kalantari E; Saeednejad Zanjani L; Abolhasani M; Asadi Lari MH; Madjd Z
Exp Mol Pathol; 2019 Jun; 108():164-172. PubMed ID: 31028726
[TBL] [Abstract][Full Text] [Related]
8. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
9. Profiles of cancer stem cell subpopulations in cholangiocarcinomas.
Cardinale V; Renzi A; Carpino G; Torrice A; Bragazzi MC; Giuliante F; DeRose AM; Fraveto A; Onori P; Napoletano C; Franchitto A; Cantafora A; Grazi G; Caporaso N; D'Argenio G; Alpini G; Reid LM; Gaudio E; Alvaro D
Am J Pathol; 2015 Jun; 185(6):1724-39. PubMed ID: 25892683
[TBL] [Abstract][Full Text] [Related]
10. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma?
Sasaki M; Sato Y; Nakanuma Y
Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959
[TBL] [Abstract][Full Text] [Related]
11. Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications.
Wu HJ; Chu PY
Int J Mol Sci; 2019 Aug; 20(17):. PubMed ID: 31450710
[TBL] [Abstract][Full Text] [Related]
12. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
[TBL] [Abstract][Full Text] [Related]
13. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
[TBL] [Abstract][Full Text] [Related]
14. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
15. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer.
Gao T; Wang M; Xu L; Wen T; Liu J; An G
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2131-40. PubMed ID: 27520310
[TBL] [Abstract][Full Text] [Related]
16. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
[TBL] [Abstract][Full Text] [Related]
17. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
18. Co-expression of YAP and TAZ associates with chromosomal instability in human cholangiocarcinoma.
Tóth M; Wehling L; Thiess L; Rose F; Schmitt J; Weiler SME; Sticht C; De La Torre C; Rausch M; Albrecht T; Grabe N; Duwe L; Andersen JB; Köhler BC; Springfeld C; Mehrabi A; Kulu Y; Schirmacher P; Roessler S; Goeppert B; Breuhahn K
BMC Cancer; 2021 Oct; 21(1):1079. PubMed ID: 34615513
[TBL] [Abstract][Full Text] [Related]
19. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
[TBL] [Abstract][Full Text] [Related]
20. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
Tao H; Tanaka T; Okabe K
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1449-1459. PubMed ID: 28382517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]